Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone …
This Phase II study evaluated analgesia, abuse liability, and cognitive performance of
hydromorphone and oral delta-9-tetrahydrocannabinol (THC; dronabinol) using a within …
hydromorphone and oral delta-9-tetrahydrocannabinol (THC; dronabinol) using a within …
Polymorphisms in the A118G SNP of the OPRM1 gene produce different experiences of opioids: A human laboratory phenotype–genotype assessment
Allelic variations in the A118G SNP of the OPRM1 gene change opioid signaling; however,
evaluations of how allelic differences may influence opioid effects are lacking. This human …
evaluations of how allelic differences may influence opioid effects are lacking. This human …
[HTML][HTML] Evaluating the abuse potential of opioids and abuse-deterrent opioid formulations: A review of clinical study methodology
B Setnik, KA Schoedel, N Levy-Cooperman… - Journal of Opioid …, 2017 - wmpllc.org
With the development of opioid abuse-deterrent formulations (ADFs), there is a need to
conduct well-designed human abuse potential studies to evaluate the effectiveness of their …
conduct well-designed human abuse potential studies to evaluate the effectiveness of their …
[HTML][HTML] Within subject, double blind, examination of opioid sensitivity in participant-reported, observed, physiologic, and analgesic outcomes
Background Inter-individual differences in opioid sensitivity may underlie different opioid risk
profiles but have often been researched in persons who have current or past opioid use …
profiles but have often been researched in persons who have current or past opioid use …
Individual differences in human opioid abuse potential as observed in a human laboratory study
Background Opioids have high abuse potential and pose a major public health concern. Yet,
a large percentage of individuals exposed to opioids do not develop problematic use …
a large percentage of individuals exposed to opioids do not develop problematic use …
Abuse potential with oral route of administration of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent …
M Darwish, M Bond, Y Ma, W Tracewell… - Pain …, 2017 - academic.oup.com
Objective. To compare the oral abuse potential of hydrocodone extended-release (ER)
tablet developed with CIMA® Abuse-Deterrence Technology with that of hydrocodone …
tablet developed with CIMA® Abuse-Deterrence Technology with that of hydrocodone …